Strides Pharma Science (NSE:STAR) GF Value Rank: 3 (As of Jul. 16, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
68 GF Score
Price ₹1,059.60
GF Value ₹781.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science GF Value Rank?

Strides Pharma Science NSE:STAR -1.07% 68 GF Value Rank is 3 as of Jul. 16, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹781.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Strides Pharma Science has the GF Value Rank of 3.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Strides Pharma Science GF Value Rank Related Terms


NSE:STAR vs ZTS, UTHR: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's GF Value Rank falls into.


NSE:STAR
68GF Score
Strides Pharma Science Ltd NSE:STAR
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 3 mean?
Strides Pharma Science (NSE:STAR) has a GF Value Rank of 3 as of Jul. 16, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Strides Pharma Science and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Strides Pharma Science's GF Value Rank has ranged from 1.00 to 10.00.
Is Strides Pharma Science's GF Value Rank too high?
Strides Pharma Science's current GF Value Rank of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's GF Value Rank compare to ZTS and UTHR?
Strides Pharma Science's GF Value Rank of 3 can be compared against companies in the Drug Manufacturers industry. Historically, Strides Pharma Science's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current GF Value Rank is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹781.13, compared to a current price of ₹1,059.60 — trading 35.6% above its estimated fair value. The current GF Value Rank is 3, which is 25% below median its 10-year median of 4.00. Strides Pharma Science's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current GF Value Rank is 3 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,059.60 is trading 35.6% above its estimated GF Value™ of ₹781.13. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • GF Value Rank: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: ₹781.13 vs. price of ₹1,059.60 (35.6% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score

Get the complete analysis for NSE:STAR

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,059.60
Price
₹781.13
GF Value